Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on December 2, 2025, in Shanghai. The primary agenda is to elect Mr. Liu Yi as an executive director. This meeting reflects the company’s ongoing efforts to strengthen its leadership structure, which could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and healthcare services.
Average Trading Volume: 9,657,638
Technical Sentiment Signal: Buy
Current Market Cap: HK$77.49B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.